Oramed Pharmaceuticals Inc. (ORMP) income statement
ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.89+0.02 (+0.52%)
Close on Nov 18, 2026Market cap $161.81MP/E 0.9Yield 6.43%
Oramed Pharmaceuticals Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- 0.7%
- Operating margin
- -726.2%
- Net margin
- 8743.5%
- Return on equity, FY2025
- 37.0%
Financial strength
- Current ratio
- 4.98
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 142.1%
Valuation
- P/E ratio
- 0.9
- Price to sales
- –
- Price to book
- –
- Dividend yield
- 6.43%
See a number that looks wrong?